Pittsburgh, PA– University of Pittsburgh Medical Center

Melanoma Clinical Trials- Recruiting

Phase
NCT01397708
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma		 Phase III
NCT00897520
Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy		 Phase III
NCT00679289
Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Melanoma		 Phase II
NCT01258855
Aldesleukin With or Without Aflibercept in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery		 Phase II
NCT01017185
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions		 Phase II
NCT00815607
Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma		 Phase II
NCT00304525
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma		 Phase II
NCT01006980
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)		 Phase II
NCT00633334
Development of Early Detection Signs for Gastrointestinal Cancer		 Phase II
NCT00390338
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma		 Phase I
NCT00871533
Pilot Study of IFN α2b for Melanoma Patients		 Phase I
NCT01366144
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction		 Phase I
NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery		 Phase I
NCT01028222
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation		 Phase I
NCT01266967
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain		 Phase I
NCT00049530
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma		 Phase I
NCT00897546
Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma		 Phase I
NCT00972933
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma
NCT00897442
Collecting Tumor Samples From Patients With Gynecological Tumors
NCT00454701
Assessment and Tracking of Long-term Alefacept Safety
Updated from clinicaltrials.gov on 8/24/2011

Comments are closed.